Beam Therapeutics Inc. — Director's Dealing 2020

Feb 6, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Beam Therapeutics Inc. (BEAM)
CIK: 0001745999
Period of Report: 2020-02-05

Reporting Person: Burrell Terry-Ann (CFO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$13.68	2029-08-31	Common Stock (390250)		Direct

Footnotes

F1: The option vests as to 25% on the first anniversary of the of the vesting commencement date, August 20, 2019, and at a rate of 2.78% each month thereafter until the option is fully vested.